Moffitt logo

Notice to Our Patients Regarding a Stolen Briefcase. Learn More

Clinical Trials Search

Clinical Trial 20056

Cancer Type: Genitourinary
Study Type: Prevention
NCT#: NCT04300855

Phase: Phase II
Prinicipal Investigator:

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Phase II Clinical Trial of Green Tea Catechins in Men on Active Surveillance (AS)

Summary

This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of whole Green Tea Catechin, (Sunphenon® 90D) containing 400 mgs (BID) vs. Placebo, administered for 24 months in a cohort of men with low to intermediate grade prostate cancer managed on active surveillance

Objective

Primary Outcome Measure: To assess the rate of clinical progression in men on active surveillance for prostate cancer (Gleason score (GS) 3+3 OR predominant Gleason grade 3 ( 3+4), ≤ 33% of biopsy cores positive for cancer and ≤ 50% involvement of any one core), treated with standardized GTC (400 mg EGCG bid) vs. placebo for 24 months, with rate of clinical progression defined as a composite outcome on repeat prostate biopsy >33% of biopsy cores positive for cancer or > 50% of any biopsy tissue core positive for cancer or adverse reclassification of Gleason sum > 3+3 or >3+4 respectively at end of study (EOS) biopsy. Secondary outcome measures: In patients randomized to receive GTC (400 mgs EGCG bid) vs. placebo: - Assess the safety of GTC (vs. Placebo) safety by evaluating incidence of adverse events and toxicities, monitored using Common Toxicity Criteria version 5.0 (monthly), CBC, CMP, LFTs at baseline, year 1 and EOS. - Assess bioavailability as indicated by change in EGCG measured in plasma at baseline, year 1 and EOS. - Assess adherence and acceptability to agent by evaluating monthly percentage compliance using agent logs (%) and pill counts monthly. - Assess patient reported symptoms by evaluating change in scores in lower urinary tract symptoms and quality of life from baseline to EOS at baseline, year 1 and EOS. - Assess change in PSA and PSA kinetics (PSA, PSA doubling time and PSA density) from serum from baseline, 6, 12, 18 and EOS. - Assess the change in 17-gene expression panel (Oncotype Dx®) from baseline to EOS using biopsy tissue. - Assess the proportion of men with no cancer in the post-intervention biopsy from baseline to EOS. - Assess changes in the microbiome from baseline to post intervention - With consent of participating subjects, create a specimen repository (serum, stool and prostate biopsies) to test future hypotheses related to prostate cancer, as and when possible.

Treatments

Therapies

Medications

Sunphenon 90D/placebo ()

Inclusion Criteria

  • Biopsy-proven (consisting of ≥ 12 tissue cores) adenocarcinoma of the prostate with cancer present in at least one biopsy core in the most recent biopsy within last 6 months(TRUS or/and mpMRI/TRUS fusion), Gleason score (3+3) or predominant Gleason pattern 3 (3+4), ≤ 33% of biopsy cores, and > Willing to start or continue on active surveillance
  • Screening serum PSA > No other prior treatment for PCa, including focal therapy
  • ECOG performance status 0−1
  • No history of renal or hepatic disease, including history of hepatitis B and C
  • Meet hematological eligibility parameters (Neutrophil count > 1,200/mm3 (≥1.2 k/μL), Stable platelet count > 75,000/mm3 (> 75k/μL) Hepatic and renal function eligibility parameters, serum total Bilirubin > Willing to abstain from consumption of any supplements containing GTC
  • Willing to restrict tea consumption to less than three (3) servings of hot tea or three (3) servings of iced tea per week
  • Willing to discontinue current vitamin/mineral supplement use and use one provided by study
  • Willing to take study agent or placebo at the dose specified with meals

  • Exclusion Criteria

  • Have had prior treatment for PCa by surgery, irradiation, local ablative (i.e., cryosurgery or high-intensity focused ultrasound), or androgen-deprivation therapy)
  • Men treated with 5- alpha-reductase inhibitors (e.g., finasteride, dutasteride)
  • Participants who have PCa with distant metastases
  • Participants who have been treated with: hormone therapy, immunotherapy, chemotherapy and/or radiation, for any malignancies within the past 2 years
  • Participants may not be receiving any other investigational agents
  • History of allergic reactions attributed to tea or compounds of similar chemical or biologic composition to green tea extracts

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.